Category
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Stem Cells & Wnt
- Hippo
- Ubiquitin
- Neuronal Signaling
- NF-κB
- GPCR & G Protein
- Endocrinology & Hormones
- Transmembrane Transporters
- Metabolism
- Proteases
- Microbiology
- Others
Archives
PI3K
Improvement of the LbCas12a-crRNA System for Efficient Gene Targeting in Tomato
4 views | Sep 16 2021
Tien Van Vu et al. demonstrated the significance of the selection of gene scissors, the appropriate design and number of LbCas12a crRNAs, the use of chemical treatments. [Read the Full Post]
PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation
17 views | Sep 02 2021
Rachel Y Chow et al. suggested that PI3K promoted BCC tumor growth by kinase-induced p21 degradation without altering HH signaling. [Read the Full Post]
Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
19 views | Sep 02 2021
Aya Takahashi et al. found that regorafenib had an activating effect on signal transducers and activators of transcription 1 (STAT1), and that regorafenib-induced HLA-I expression was dependent on the augmented IFNγ/STAT1 signaling pathway. [Read the Full Post]
Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments
34 views | Aug 31 2021
Chaitanya N Hiremath found that drugs with strong safety profiles included molnupiravir (EIDD-2801), moderate safety profiles included dexamethasone, and weak safety profiles included lopinavir. [Read the Full Post]
High-Throughput Screening Identifies Ascorbyl Palmitate As a SIRT2 Deacetylase and Defatty-Acylase Inhibitor
40 views | Aug 31 2021
Jun Young Hong et al. discovered novel SIRT2 deacylase inhibitors and presented a screening approach that could be applied on a larger scale. [Read the Full Post]
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
31 views | Aug 05 2021
Grégoire Marret et al. found that copanlisib combined with cetuximab demonstrated unfavorable toxicity and limited efficacy in heavily pretreated recurrent and/or metastatic HNSCC patients. [Read the Full Post]
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
27 views | Aug 04 2021
Ana Portelinha et al. found that the PI3K inhibitor copanlisib enhanced the antiproliferative activity of ASN007 both in vitro and in vivo due to dual inhibition of RAS/MAPK and PI3K survival pathways. [Read the Full Post]
Idelalisib immune-related toxicity is associated with improved treatment response
40 views | Aug 03 2021
Nina D Wagner-Johnston et al. showed a trend correlating idelalisib-induced Grade ≥3 irAEs with improved efficacy. [Read the Full Post]
Hydrogen-Rich Medium Regulates Cr(VI)-Induced ER Stress and Autophagy Signaling in DF-1 Cells
41 views | Aug 02 2021
Kangping Liu et al. found that HRM could protect cells from damage induced by Cr(VI), and played a role by inhibiting ER stress-mediated autophagy. [Read the Full Post]
Peptide 11R‑VIVIT promotes fracture healing in osteoporotic rats
159 views | Jul 20 2021
Changju Hou et al. demonstrated that 11R‑VIVIT promoted fracture healing in osteoporotic rats and enhanced the osteogenic differentiation of osteoporotic BMSCs by dysregulating the AKT/NFATc1 signaling pathway. [Read the Full Post]
